One World Trade Center
Suite 8500
New York, NY 10007
United States
212-220-6633
https://www.mindmed.co
Sector(es):
Industria:
Empleados a tiempo completo: 57
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Robert Barrow | CEO & Director | 1.27M | N/D | 1989 |
Mr. Schond L. Greenway M.B.A. | Chief Financial Officer | 831.84k | N/D | 1972 |
Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer | 900.04k | N/D | 1980 |
Dr. Miriam Halperin Wernli M.B.A., Ph.D. | Executive President | 755.08k | N/D | 1953 |
Dr. Scott M. Freeman M.D. | Co-Founder & Clinical Advisor | 430k | N/D | 1957 |
Mr. Leonard Latchman | Co-founder | N/D | N/D | N/D |
Ms. Carrie F. Liao C.P.A., CGMA | VP & Chief Accounting Officer | N/D | N/D | 1966 |
Mr. Mark R. Sullivan J.D. | Chief Legal Officer & Corporate Secretary | N/D | N/D | 1971 |
Dr. Francois P. Lilienthal M.B.A., M.D. | Chief Commercial Officer | N/D | N/D | N/D |
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
La calificación ISS Governance QuickScore de Mind Medicine (MindMed) Inc. a partir del 1 de mayo de 2024 es 6. Las puntuaciones principales son Auditoría: 8; Junta: 5; Derechos del accionista: 3; Compensación: 8.